On April 24, Gelonghui Pharmaceuticals (03933.HK) announced that amoxicillin clavulanate potassium tablets (specification: 0.375g) declared by the Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, were approved by the China National Drug Administration and passed the consistent evaluation of the quality and efficacy of generic drugs.
Amoxicillin clavulanate potassium tablets are a penicillin-type broad-spectrum antibiotic. Clinically, it is commonly used to treat infections caused by beta-lactamase-producing bacteria, such as respiratory infections, skin and soft tissue infections, and urinary infections. It has clear curative effects, is safe and reliable, and is an antibacterial drug widely used in basic clinical use. Currently, amoxicillin and clavulanate potassium are Class A drugs in the National Medicines List (2018 edition) and the National Medical Insurance Catalogue (2022 edition).
This approval will further enhance the brand value of the Group's products and enhance market competitiveness. In the future, the company will continue to work on developing new products and promoting consistency evaluations, which is expected to generate greater benefits for the company and its shareholders.